A comparison of natalizumab’s effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients
The favorable clinical, radiological, and neuropsychological outcomes observed in this study support the use of natalizumab as a viable treatment option in POMS.
Authors
- Alessandro Miscioscia (ORCID: https://orcid.org/0000-0001-7465-6246)
- Alice Riccardi
- Marco Puthenparampil (ORCID: https://orcid.org/0000-0002-2313-8462)
- Margherita Nosadini (ORCID: https://orcid.org/0000-0002-6395-7614)
- Paolo Gallo (ORCID: https://orcid.org/0000-0003-3886-4181)
- Stefano Sartori (ORCID: https://orcid.org/0000-0002-0012-6848)
- Giovanni Zanotelli
- Graziana Scialpi
- Marta Gaggiola
- Francesca Rinaldi (ORCID: https://orcid.org/0000-0002-6390-1450)
- Angela Berardi
- Paola Perini (ORCID: https://orcid.org/0009-0008-9628-1180)
Institutions
- University of Padua (IT)
- Azienda Ospedale - Università Padova (IT)
- Città della Speranza Foundation (IT)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.3389/fneur.2024.1475161
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Biogen
- Università degli Studi di Padova